Samir Gupta1,2,3, Elizabeth T Jacobs4, John A Baron5, David A Lieberman6, Gwen Murphy7, Uri Ladabaum8, Amanda J Cross9, Rodrigo Jover10, Lin Liu3,11, Maria Elena Martinez3,11. 1. Department of Medicine, Section of Gastroenterology, Veteran Affairs San Diego Healthcare System, San Diego, California, USA. 2. Division of Gastroenterology, Department of Internal Medicine, University of California San Diego, La Jolla, California, USA. 3. Moores Cancer Center, University of California San Diego, La Jolla, California, USA. 4. Department of Epidemiology and Biostatistics, Arizona Cancer Center, Arizona College of Public Health, University of Arizona, Tucson, Arizona, USA. 5. Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA. 6. Division of Gastroenterology and Hepatology, Portland Veterans Affairs Medical Cente and Oregon Health and Science University, Portland, Oregon, USA. 7. Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA. 8. Division of Gastroenterology/Hepatology, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA. 9. Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Rockville, Maryland, USA. 10. Unidad de Gastroenterología, Hospital General Universitario de Alicante, Instituto de Investigación Sanitaria (ISABIAL), Alicante, Spain. 11. Department of Family Medicine and Public Health, University of California San Diego, La Jolla, California, USA.
Abstract
OBJECTIVE: For individuals with 1-2 small (<1 cm) low-risk colorectal adenomas, international guidelines range from no surveillance to offering surveillance colonoscopy in 5-10 years. We hypothesised that the risks for metachronous advanced neoplasia (AN) among patients with low-risk adenomas differ based on clinical factors distinct from those currently used. DESIGN: We pooled data from seven prospective studies to assess the risk of metachronous AN. Two groups with 1-2 small adenomas were defined based on guidelines from the UK (n=4516) or the European Union (EU)/US (n=2477). RESULTS: Absolute risk of metachronous AN ranged from a low of 2.9% to a high of 12.2%, depending on specific risk factor and guideline used. For the UK group, the highest absolute risks for metachronous AN were found among individuals with a history of prior polyp (12.2%), villous histology (12.2%), age ≥70 years (10.9%), high-grade dysplasia (10.9%), any proximal adenoma (10.2%), distal and proximal adenoma (10.8%) or two adenomas (10.1%). For the EU/US group, the highest absolute risks for metachronous AN were among individuals with a history of prior polyp (11.5%) or the presence of both proximal and distal adenomas (11.0%). In multivariate analyses, strong associations for increasing age and history of prior polyps and odds of metachronous AN were observed, whereas more modest associations were shown for baseline proximal adenomas and those with villous features. CONCLUSIONS: Risks of metachronous AN among individuals with 1-2 small adenomas vary according to readily available clinical characteristics. These characteristics may be considered for recommending colonoscopy surveillance and require further investigation. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
OBJECTIVE: For individuals with 1-2 small (<1 cm) low-risk colorectal adenomas, international guidelines range from no surveillance to offering surveillance colonoscopy in 5-10 years. We hypothesised that the risks for metachronous advanced neoplasia (AN) among patients with low-risk adenomas differ based on clinical factors distinct from those currently used. DESIGN: We pooled data from seven prospective studies to assess the risk of metachronous AN. Two groups with 1-2 small adenomas were defined based on guidelines from the UK (n=4516) or the European Union (EU)/US (n=2477). RESULTS: Absolute risk of metachronous AN ranged from a low of 2.9% to a high of 12.2%, depending on specific risk factor and guideline used. For the UK group, the highest absolute risks for metachronous AN were found among individuals with a history of prior polyp (12.2%), villous histology (12.2%), age ≥70 years (10.9%), high-grade dysplasia (10.9%), any proximal adenoma (10.2%), distal and proximal adenoma (10.8%) or two adenomas (10.1%). For the EU/US group, the highest absolute risks for metachronous AN were among individuals with a history of prior polyp (11.5%) or the presence of both proximal and distal adenomas (11.0%). In multivariate analyses, strong associations for increasing age and history of prior polyps and odds of metachronous AN were observed, whereas more modest associations were shown for baseline proximal adenomas and those with villous features. CONCLUSIONS: Risks of metachronous AN among individuals with 1-2 small adenomas vary according to readily available clinical characteristics. These characteristics may be considered for recommending colonoscopy surveillance and require further investigation. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
Authors: David A Lieberman; Douglas K Rex; Sidney J Winawer; Francis M Giardiello; David A Johnson; Theodore R Levin Journal: Gastroenterology Date: 2012-07-03 Impact factor: 22.682
Authors: D S Alberts; M E Martínez; D J Roe; J M Guillén-Rodríguez; J R Marshall; J B van Leeuwen; M E Reid; C Ritenbaugh; P A Vargas; A B Bhattacharyya; D L Earnest; R E Sampliner Journal: N Engl J Med Date: 2000-04-20 Impact factor: 91.245
Authors: A Schatzkin; E Lanza; D Corle; P Lance; F Iber; B Caan; M Shike; J Weissfeld; R Burt; M R Cooper; J W Kikendall; J Cahill Journal: N Engl J Med Date: 2000-04-20 Impact factor: 91.245
Authors: David S Alberts; María Elena Martínez; Lisa M Hess; Janine G Einspahr; Sylvan B Green; A K Bhattacharyya; Jose Guillen; Mary Krutzsch; Ashok K Batta; Gerald Salen; Liane Fales; Kris Koonce; Dianne Parish; Mary Clouser; Denise Roe; Peter Lance Journal: J Natl Cancer Inst Date: 2005-06-01 Impact factor: 13.506
Authors: Øyvind Holme; Magnus Løberg; Mette Kalager; Michael Bretthauer; Miguel A Hernán; Eline Aas; Tor J Eide; Eva Skovlund; Jørn Schneede; Kjell Magne Tveit; Geir Hoff Journal: JAMA Date: 2014-08-13 Impact factor: 56.272
Authors: Lindsey A Torre; Freddie Bray; Rebecca L Siegel; Jacques Ferlay; Joannie Lortet-Tieulent; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2015-02-04 Impact factor: 508.702
Authors: Aasma Shaukat; Steven J Mongin; Mindy S Geisser; Frank A Lederle; John H Bond; Jack S Mandel; Timothy R Church Journal: N Engl J Med Date: 2013-09-19 Impact factor: 91.245
Authors: S J Winawer; A G Zauber; M J O'Brien; M N Ho; L Gottlieb; S S Sternberg; J D Waye; J Bond; M Schapiro; E T Stewart Journal: N Engl J Med Date: 1993-04-01 Impact factor: 91.245
Authors: E R Greenberg; J A Baron; T D Tosteson; D H Freeman; G J Beck; J H Bond; T A Colacchio; J A Coller; H D Frankl; R W Haile Journal: N Engl J Med Date: 1994-07-21 Impact factor: 91.245
Authors: Joseph C Anderson; John A Baron; Dennis J Ahnen; Elizabeth L Barry; Roberd M Bostick; Carol A Burke; Robert S Bresalier; Timothy R Church; Bernard F Cole; Marcia Cruz-Correa; Adam S Kim; Leila A Mott; Robert S Sandler; Douglas J Robertson Journal: Gastroenterology Date: 2017-02-20 Impact factor: 22.682
Authors: Reinier G S Meester; Iris Lansdorp-Vogelaar; Sidney J Winawer; Ann G Zauber; Amy B Knudsen; Uri Ladabaum Journal: Ann Intern Med Date: 2019-09-24 Impact factor: 25.391
Authors: Samir Gupta; David Lieberman; Joseph C Anderson; Carol A Burke; Jason A Dominitz; Tonya Kaltenbach; Douglas J Robertson; Aasma Shaukat; Sapna Syngal; Douglas K Rex Journal: Gastroenterology Date: 2020-02-07 Impact factor: 22.682
Authors: Samir Gupta; David Lieberman; Joseph C Anderson; Carol A Burke; Jason A Dominitz; Tonya Kaltenbach; Douglas J Robertson; Aasma Shaukat; Sapna Syngal; Douglas K Rex Journal: Gastrointest Endosc Date: 2020-02-07 Impact factor: 9.427
Authors: Samir Gupta; David Lieberman; Joseph C Anderson; Carol A Burke; Jason A Dominitz; Tonya Kaltenbach; Douglas J Robertson; Aasma Shaukat; Sapna Syngal; Douglas K Rex Journal: Am J Gastroenterol Date: 2020-03 Impact factor: 12.045
Authors: Naim Abu-Freha; Lior H Katz; Revital Kariv; Elez Vainer; Ido Laish; Nathan Gluck; Elizabeth E Half; Zohar Levi Journal: United European Gastroenterol J Date: 2021-06-02 Impact factor: 4.623